{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:09:18Z","timestamp":1759410558767},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.vaccine.2015.03.085","type":"journal-article","created":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T18:19:53Z","timestamp":1429985993000},"page":"C30-C35","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S3","title":["The case for a typhoid vaccine probe study and overview of design elements"],"prefix":"10.1016","volume":"33","author":[{"given":"Bradford D.","family":"Gessner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Elizabeth","family":"Halloran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.03.085_bib0170","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(13)61682-7","article-title":"Use of vaccines as probes to define disease burden","volume":"383","author":"Feikin","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0175","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1016\/j.vaccine.2014.04.019","article-title":"Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy","volume":"32","author":"Gessner","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(04)17664-2","article-title":"Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial","volume":"365","author":"Gessner","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0185","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0140-6736(05)71876-6","article-title":"Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial","volume":"365","author":"Cutts","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0190","doi-asserted-by":"crossref","first-page":"A52","DOI":"10.1016\/j.vaccine.2011.08.043","article-title":"Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya","volume":"30S","author":"Feikin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0195","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2214-109X(14)70301-8","article-title":"Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment","volume":"2","author":"Mogasale","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0200","doi-asserted-by":"crossref","first-page":"010401","DOI":"10.7189\/jogh.01.010401","article-title":"Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010","volume":"2","author":"Buckle","year":"2012","journal-title":"J Glob Health"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0205","first-page":"117","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death 1990\u20132013: a systematic analysis for the global burden of disease study 2013","volume":"3850","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0210","doi-asserted-by":"crossref","first-page":"e0029119","DOI":"10.1371\/journal.pone.0029119","article-title":"Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in Africa","volume":"7","author":"Breiman","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0215","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3201\/eid1611.100388","article-title":"Typhoid fever among children, Ghana","volume":"16","author":"Marks","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0220","first-page":"1","article-title":"Summary of conclusions and recommendations 17\u201319 September 2014 meeting","volume":"90","author":"World Health Organization","year":"2015","journal-title":"Wkly Epidemiolog Rep"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0225","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0140-6736(13)62708-7","article-title":"Typhoid fever","volume":"385","author":"Wain","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0230","first-page":"253","article-title":"The burden of enteric fever","volume":"2","author":"Kothari","year":"2008","journal-title":"J Infect Dev Countries"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0235","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0140-6736(98)09001-1","article-title":"Typhoid fever in children aged less than 5 years","volume":"354","author":"Sinha","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0240","doi-asserted-by":"crossref","first-page":"e93784","DOI":"10.1371\/journal.pone.0093784","article-title":"Case fatality rate and length of hospital stay among patients with typhoid intestinal perforation in developing countries: a systematic literature review","volume":"9","author":"Mogasale","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0245","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"The RTS","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0250","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1473-3099(12)70196-2","article-title":"Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study","volume":"12","author":"Khatib","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0255","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa0807521","article-title":"A cluster-randomized effectiveness trial of Vi typhoid vaccine in India","volume":"361","author":"Sur","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0260","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1016\/j.vaccine.2012.06.015","article-title":"Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi Pakistan","volume":"30","author":"Khan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0265","doi-asserted-by":"crossref","first-page":"e2642","DOI":"10.1371\/journal.pntd.0002642","article-title":"Dynamics of typhoid in South Asia: a mathematical modeling study","volume":"8","author":"Pitzer","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0270","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/ije\/29.4.753","article-title":"Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population","volume":"29","author":"Moulton","year":"2000","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0275","first-page":"CD001261","article-title":"Vaccines for preventing typhoid fever","volume":"1","author":"Anwar","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0280","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/S0140-6736(09)61297-6","article-title":"Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial","volume":"374","author":"Sur","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0285","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2471\/BLT.07.044503","article-title":"Vaccines to prevent pneumonia and improve child survival","volume":"86","author":"Madhi","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0290","series-title":"Bharat Biotech Typbar TCV package insert","author":"Bharat Biotech Typbar","year":"2015"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0295","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/CVI.00532-10","article-title":"The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines","volume":"18","author":"Thiem","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0300","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomized, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0305","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0310","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(13)62707-5","article-title":"Current status of rabies and prospects for elimination","volume":"384","author":"Fooks","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0315","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0320","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1471-2334-10-186","article-title":"High rate of pneumococcal bacgteremia in a prospective cohort of older children and adults in an area of high HIV prevalence in rural western Kenya","volume":"10","author":"Feikin","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0325","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1093\/ije\/28.2.319","article-title":"Simple sample size calculation for cluster-randomized trials","volume":"28","author":"Hayes","year":"1999","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2015.03.085_bib0330","series-title":"Cluster randomised trials: a practical approach","author":"Hayes","year":"2009"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T06:24:40Z","timestamp":1537683880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15004156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":33,"alternative-id":["S0264410X15004156"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.085","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The case for a typhoid vaccine probe study and overview of design elements","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}